Author: Wehkamp, U; Mitteldorf, C; Stendel, S; Stranzenbach, R; Nicolay, J P; Wobser, M; Weichenthal, M; Schneiderbauer, R; Klemke, C-D; Hillen, U; Kempf, W; Assaf, C
Title: Most rare subtypes of cutaneous lymphoma display variable CD30 expression. Analysis of the German Cutaneous Lymphoma Network. Cord-id: ev53o7pc Document date: 2021_1_22
ID: ev53o7pc
Snippet: CD30, also known as tumor necrosis factor receptor 8 (TNF-R 8), was primarily called Ki-1 and is a cell surface molecule which has first been described from a group of pathologists from Kiel in 1982.1 CD30 can be targeted with the drug brentuximab-vedotin (BV), which is approved for relapsed or refractory CD30+ cutaneous T-cell lymphoma (CTCL) including primary cutaneous anaplastic large cell lymphoma and CD30+ mycosis fungoides and Sézary syndrome.
Document: CD30, also known as tumor necrosis factor receptor 8 (TNF-R 8), was primarily called Ki-1 and is a cell surface molecule which has first been described from a group of pathologists from Kiel in 1982.1 CD30 can be targeted with the drug brentuximab-vedotin (BV), which is approved for relapsed or refractory CD30+ cutaneous T-cell lymphoma (CTCL) including primary cutaneous anaplastic large cell lymphoma and CD30+ mycosis fungoides and Sézary syndrome.
Search related documents:
Co phrase search for related documents- Try single phrases listed below for: 1
Co phrase search for related documents, hyperlinks ordered by date